Ernexa Therapeutics Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23.3M | $21.3M | $22.3M | $24.5M | $26.0M | $23.7M | $24.1M | $23.9M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $72.0K | $139.0K | — | — | — | — | — | — |
| SG&A Expense | $14.5M | $15.6M | $16.5M | $18.1M | $18.4M | $16.2M | $18.2M | $20.4M |
| Operating Income | $203.0K | $-1.4M | $-2.3M | $-6.9M | $-4.7M | $-1.1M | $-1.1M | $-3.3M |
| Operating Margin | 0.9% | -6.6% | -10.2% | -28.1% | -18.2% | -4.7% | -4.4% | -13.7% |
| Interest Expense | $296.0K | $425.0K | $517.0K | $283.0K | $223.0K | $26.0K | $44.0K | $52.0K |
| Pretax Income | $-323.0K | $-1.0M | $-2.9M | $-7.2M | $-4.9M | $-1.0M | $-1.1M | $-3.3M |
| Income Tax Expense | $-64.0K | $66.0K | $38.0K | $12.0K | $84.0K | $46.0K | $-83.0K | $163.0K |
| Net Income | $-259.0K | $-1.1M | $-2.9M | $-7.2M | $-5.0M | $-1.1M | $-995.0K | $-3.4M |
| Net Margin | -1.1% | -5.1% | -13.1% | -29.5% | -19.3% | -4.4% | -4.1% | -14.3% |
| EPS (Basic) | $-0.01 | $-0.06 | $-0.22 | $-0.56 | $-0.01 | $0.00 | $0.00 | $-0.01 |
| EPS (Diluted) | $-0.01 | $-0.06 | $-0.22 | $-0.56 | $-0.01 | $0.00 | $0.00 | $-0.01 |
| Shares Outstanding (Basic) | 20.1M | 17.6M | 15.8M | 12.9M | 646.6M | 550.5M | 483.3K | 422.8M |
| Shares Outstanding (Diluted) | 20.1M | 17.6M | 15.8M | 12.9M | 646.6M | 550.5M | 483.3K | 422.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |